JP2001316293A5 - - Google Patents

Info

Publication number

JP2001316293A5

JP2001316293A5 JP2001047695A JP2001047695A JP2001316293A5 JP 2001316293 A5 JP2001316293 A5 JP 2001316293A5 JP 2001047695 A JP2001047695 A JP 2001047695A JP 2001047695 A JP2001047695 A JP 2001047695A JP 2001316293 A5 JP2001316293 A5 JP 2001316293A5

Authority

JP

Japan

Prior art keywords

medicament according

glucosidase inhibitor

mitiglinide

repaglinide

insulin secretagogue

Prior art date

2001-02-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 description 17
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 9
• 239000003888 alpha glucosidase inhibitor Substances 0.000 description 9
• 229940122199 Insulin secretagogue Drugs 0.000 description 6
• BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 6
• FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 5
• 229960003365 mitiglinide Drugs 0.000 description 5
• WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 5
• 229960002354 repaglinide Drugs 0.000 description 5
• FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical group OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 4
• 229960001729 voglibose Drugs 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 238000011282 treatment Methods 0.000 description 2
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical group O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 208000002705 Glucose Intolerance Diseases 0.000 description 1
• IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical group OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
• 229960002632 acarbose Drugs 0.000 description 1
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
• 229950000269 emiglitate Drugs 0.000 description 1
• NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical group C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 229960001110 miglitol Drugs 0.000 description 1
• 201000009104 prediabetes syndrome Diseases 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1